infliximab
Celltrion’s infliximab biosimilar Remsima secures European approval in five indications
July 27, 2020Manufacturing and Production, Sales and Marketing celltrion, infliximab, pharma, remsima
The subcutaneous (SC) formulation of Remsima, Celltrion’s biosimilar version of infliximab, has secured approval from the European Commission covering five …
Europe approves first subcutaneous version of biosimilar infliximab
November 26, 2019Manufacturing and Production, Sales and Marketing arthritis, biosimilars, celltrion, infliximab, pharma
The European Commission has chosen to authorise Celltrion Healthcare’s Remsima SC, a biosimilar of infliximab and the first subcutaneous formulation …
Celltrion’s subcutaneous infliximab biosimilar secures CHMP recommendation
September 24, 2019Manufacturing and Production, Sales and Marketing EMA, EU, Europe, biosimilar, celltrion, infliximab, pharma
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has given its recommendation to Celltrion’s CT-P13 SC, the subcutaneous …
US court upholds ruling that J&J’s Remicade patent is invalid
January 24, 2018Research and Development, Sales and Marketing J&J, JJ, Johnson & Johnson, Remicade, biosimilars, infliximab, patent, pharma
The US Court of Appeals for the Federal Circuit has judged that Johnson & Johnson’s patent for its best-selling arthritis …
J&J loses Remicade patent fight, pledges to continue fight against biosimilars
August 18, 2016Research and Development, Sales and Marketing Johnson and Johnson, Remicade, biosimilar, biosimilars, infliximab, patent
Johnson and Johnson has announced that it has lost in a patent dispute between biosimilar makers Celltrion and Hospira, relating …
Samsung Bioepis’ Remicade biosimilar set for CHMP verdict
March 31, 2016Medical Communications, Sales and Marketing Flixabi, Remicade, Samsung Bioepis, biosimilars, infliximab
Samsung Bioepis has confirmed that the European Commission’s scientific committee, the CHMP, is this week discussing the approval of its …
Napp launches biosimilar in UK
February 25, 2015Research and Development, Sales and Marketing Hospira, Napp, Remicade, anti-TNF biologic, biosimilar, infliximab, remsima
Napp Pharmaceuticals has launched its own biosimilar version of an anti-TNF biologic in Europe paving the way for patient access …
Hospira launches biosimilar monoclonal antibody
February 16, 2015Research and Development, Sales and Marketing MSD, Merck, Remicade, biosimilar. hospira, inflectra, infliximab
Hospira has won the race to become the first company to launch a biosimilar version of an anti-TNF biologic, after …
Abbott wins $1.7bn Humira case
February 24, 2011Sales and Marketing Abbott, Abbott Laboratories, Centocor, Johnson and Johnson, Remicade, Simponi, TNF, golimumab, infliximab, rheumatoid arthritis
Abbott has been saved from paying Johnson & Johnson $1.7 billion after a US appeals court quashed a patent dispute …
Latest content
Five Facts about cardiovascular disease
